S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
4 stocks benefitting from NVIDIA's explosive growth
Blue Chips And Billionaires Quietly Investing In "The New Oil" (Ad)
How this AP photographer captured a unique splash at the swimming worlds with an underwater camera
Analysts boosted Snowflake stock, big firms are buying now
Blue Chips And Billionaires Quietly Investing In "The New Oil" (Ad)
Is CRISPR Therapeutics the NVIDIA of gene editing?
6 reasons to buy Teva Pharmaceuticals stock sooner than later
Blue Chips And Billionaires Quietly Investing In "The New Oil" (Ad)
First it was Tyson stock, now this food company is set to rally
Block's multiple ecosystems drive shares higher on 2024 outlook
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
4 stocks benefitting from NVIDIA's explosive growth
Blue Chips And Billionaires Quietly Investing In "The New Oil" (Ad)
How this AP photographer captured a unique splash at the swimming worlds with an underwater camera
Analysts boosted Snowflake stock, big firms are buying now
Blue Chips And Billionaires Quietly Investing In "The New Oil" (Ad)
Is CRISPR Therapeutics the NVIDIA of gene editing?
6 reasons to buy Teva Pharmaceuticals stock sooner than later
Blue Chips And Billionaires Quietly Investing In "The New Oil" (Ad)
First it was Tyson stock, now this food company is set to rally
Block's multiple ecosystems drive shares higher on 2024 outlook
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
4 stocks benefitting from NVIDIA's explosive growth
Blue Chips And Billionaires Quietly Investing In "The New Oil" (Ad)
How this AP photographer captured a unique splash at the swimming worlds with an underwater camera
Analysts boosted Snowflake stock, big firms are buying now
Blue Chips And Billionaires Quietly Investing In "The New Oil" (Ad)
Is CRISPR Therapeutics the NVIDIA of gene editing?
6 reasons to buy Teva Pharmaceuticals stock sooner than later
Blue Chips And Billionaires Quietly Investing In "The New Oil" (Ad)
First it was Tyson stock, now this food company is set to rally
Block's multiple ecosystems drive shares higher on 2024 outlook
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
4 stocks benefitting from NVIDIA's explosive growth
Blue Chips And Billionaires Quietly Investing In "The New Oil" (Ad)
How this AP photographer captured a unique splash at the swimming worlds with an underwater camera
Analysts boosted Snowflake stock, big firms are buying now
Blue Chips And Billionaires Quietly Investing In "The New Oil" (Ad)
Is CRISPR Therapeutics the NVIDIA of gene editing?
6 reasons to buy Teva Pharmaceuticals stock sooner than later
Blue Chips And Billionaires Quietly Investing In "The New Oil" (Ad)
First it was Tyson stock, now this food company is set to rally
Block's multiple ecosystems drive shares higher on 2024 outlook
NASDAQ:IRIX

IRIDEX (IRIX) Stock Price, News & Analysis

$2.55
+0.07 (+2.82%)
(As of 02/23/2024 08:53 PM ET)
Today's Range
$2.45
$2.55
50-Day Range
$2.45
$3.10
52-Week Range
$1.31
$3.48
Volume
18,900 shs
Average Volume
26,135 shs
Market Capitalization
$41.44 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$2.00

IRIDEX MarketRank™ Stock Analysis

Analyst Rating
0.00 Rating Score
Upside/​Downside
21.6% Downside
$2.00 Price Target
Short Interest
Healthy
2.70% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.48mentions of IRIDEX in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.46) to ($0.26) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.06 out of 5 stars

Computer And Technology Sector

571st out of 577 stocks

Electromedical Equipment Industry

21st out of 21 stocks


IRIX stock logo

About IRIDEX Stock (NASDAQ:IRIX)

IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of retinal disorders; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments. The company also provides delivery devices, including TxCell scanning laser delivery system that allows the physician to perform multi-spot pattern scanning; slit lamp adapter, which allows the physician to utilize a standard slit lamp in diagnosis and treatment procedures; and laser indirect ophthalmoscope for use in procedures to treat peripheral retinal disorders. It offers MicroPulse P3 Probe, which is used with its Cylco G6 laser system to perform MicroPulse transscleral laser therapy; G-Probe, which is used in procedures to treat uncontrolled glaucoma; G-Probe and G-Probe Illuminate, which are used in procedures to treat refractory glaucoma; and EndoProbe family of products for use in vitrectomy procedures. The company serves ophthalmologists, research and teaching hospitals, government installations, surgical centers, hospitals, veterinary practices, and office clinics. It markets its products through direct and independent sales force in the United States, as well as through independent distributors internationally. The company was formerly known as IRIS Medical Instruments, Inc. and changed its name to IRIDEX Corporation in November 1995. IRIDEX Corporation was incorporated in 1989 and is headquartered in Mountain View, California.

IRIX Stock Price History

IRIX Stock News Headlines

Iridex Stock (NASDAQ:IRIX), Short Interest Report
Blue Chips And Billionaires Quietly Investing In "The New Oil"
They're as essential to the tech and AI revolutions as oil was to the industrial revolution. Known as rare earth elements or REEs, these relatively unheard of commodities are essential to semiconductor chips, renewable energy, electric vehicles, and more.
IRIDEX (NASDAQ:IRIX) Now Covered by Analysts at StockNews.com
Iridex: Q3 Earnings Insights
Blue Chips And Billionaires Quietly Investing In "The New Oil"
They're as essential to the tech and AI revolutions as oil was to the industrial revolution. Known as rare earth elements or REEs, these relatively unheard of commodities are essential to semiconductor chips, renewable energy, electric vehicles, and more.
IRIDEX Corp IRIX
Dow Gains Over 100 Points; Fed Leaves Interest Rates Unchanged
BYU, WE and IRIX among pre-market losers
Iridex Reports Second Quarter 2023 Financial Results
IRIDEX earnings preview: what Wall Street is expecting
See More Headlines
Receive IRIX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for IRIDEX and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/11/2021
Today
2/25/2024
Next Earnings (Estimated)
3/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Industry
Electromedical equipment
Sub-Industry
N/A
Current Symbol
NASDAQ:IRIX
Employees
130
Year Founded
1989

Price Target and Rating

Average Stock Price Target
$2.00
High Stock Price Target
$2.00
Low Stock Price Target
$2.00
Potential Upside/Downside
-21.6%
Consensus Rating
Rating Score (0-4)
0.00
Research Coverage
0 Analysts

Profitability

Net Income
$-7,550,000.00
Pretax Margin
-14.13%

Debt

Sales & Book Value

Annual Sales
$56.97 million
Book Value
$1.08 per share

Miscellaneous

Free Float
15,241,000
Market Cap
$41.44 million
Optionable
Optionable
Beta
0.82

Social Links

Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report














IRIX Stock Analysis - Frequently Asked Questions

What is IRIDEX's stock price target for 2024?

0 analysts have issued 12-month target prices for IRIDEX's shares. Their IRIX share price targets range from $2.00 to $2.00. On average, they predict the company's stock price to reach $2.00 in the next year. This suggests that the stock has a possible downside of 21.6%.
View analysts price targets for IRIX
or view top-rated stocks among Wall Street analysts.

How have IRIX shares performed in 2024?

IRIDEX's stock was trading at $2.81 at the start of the year. Since then, IRIX stock has decreased by 9.3% and is now trading at $2.55.
View the best growth stocks for 2024 here
.

Are investors shorting IRIDEX?

IRIDEX saw a decline in short interest in the month of January. As of January 31st, there was short interest totaling 326,300 shares, a decline of 8.0% from the January 15th total of 354,600 shares. Based on an average trading volume of 51,600 shares, the days-to-cover ratio is presently 6.3 days. Currently, 2.7% of the shares of the company are short sold.
View IRIDEX's Short Interest
.

When is IRIDEX's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 14th 2024.
View our IRIX earnings forecast
.

How were IRIDEX's earnings last quarter?

IRIDEX Co. (NASDAQ:IRIX) announced its quarterly earnings results on Thursday, November, 11th. The medical equipment provider reported ($0.14) earnings per share for the quarter, topping analysts' consensus estimates of ($0.15) by $0.01. The medical equipment provider had revenue of $13.26 million for the quarter, compared to analysts' expectations of $11.90 million. IRIDEX had a negative net margin of 14.21% and a negative trailing twelve-month return on equity of 52.93%. During the same quarter last year, the company earned ($0.12) earnings per share.

What is Theodore A. Boutacoff's approval rating as IRIDEX's CEO?

7 employees have rated IRIDEX Chief Executive Officer Theodore A. Boutacoff on Glassdoor.com. Theodore A. Boutacoff has an approval rating of 64% among the company's employees.

What other stocks do shareholders of IRIDEX own?

Based on aggregate information from My MarketBeat watchlists, some companies that other IRIDEX investors own include NVIDIA (NVDA), Trevena (TRVN), CTI BioPharma (CTIC), Agile Therapeutics (AGRX), Genocea Biosciences (GNCA), Idera Pharmaceuticals (IDRA), Lipocine (LPCN), Rigel Pharmaceuticals (RIGL) and SCYNEXIS (SCYX).

Who are IRIDEX's major shareholders?

IRIDEX's stock is owned by a variety of institutional and retail investors. Top institutional investors include AMH Equity Ltd (2.44%), Dimensional Fund Advisors LP (0.30%), Citadel Advisors LLC (0.00%), Northern Trust Corp (0.17%), Simplex Trading LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Nandini Devi and Robert Earle Grove.
View institutional ownership trends
.

How do I buy shares of IRIDEX?

Shares of IRIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:IRIX) was last updated on 2/26/2024 by MarketBeat.com Staff